Clinical trial
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic…
NCT00331682 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00331682 |
|---|---|
| Title | Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer |
| Official title | An Open-Label, Non-Randomized Phase II Study of Alvocidib (Flavopiridol) in Combination With Docetaxel in Refractory, Metastatic Pancreatic Cancer (NCI #6366) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | alvocidib, docetaxel |
| Enrollment | 10 |
| Start date | Mar 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | May 31, 2006 |
| Last update posted | May 28, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: